Menu

Home

ChitoLytic Diagnostics is developing the latest paper-based Lab-In-Hand point-of-care (POC) diagnostic technologies.  The diagnostic tests from our technology will make health information more accessible to who and where it’s needed to improve and save lives.

Our paper-based microfluidics platform technologies disrupt by decentralizing testing. They facilitate devices that deliver laboratory-like molecular accuracy at the POC (e.g., homes, work, schools, events, clinics, remote and low-resourced areas, etc.).  On-device test results happen in minutes, and at an extremely low price. They literally move complicated, costly testing from the lab to the palm of your hand where tests can be taken reliably anywhere, anytime, and by anyone.

Disclaimers: Device images are for illustrative purposes only. At this time, more detailed technical information about our technologies and devices can be provided by contacting us and on a limited basis.

Lab-In-Hand Devices Under Accelerated Development

COVID-19 Lab-In-Hand Test

Nucleic Acid (Molecular) Rapid Point-of-Care

Next-generation COVID-19 home test for lab-like accuracy in 20-minutes. Test anywhere, anytime, by anyone with no equipment nor a technician is required.  Test frequently with simple-to-use, COVID-19 Lab-In-Hand tests for ~$10 – $20/test at home, work, schools, events, clinics, etc.

Its technology is an advancement over other POC rapid tests. It represents the next generation in molecular diagnostic testing by providing the accuracy of laboratory molecular testing. But it does so by delivering rapid results (~20 minutes) at the point-of-need. It doesn’t require equipment, power (electricity or batteries), or a technician. It’s extremely affordable and simple to use, like a simple pregnancy test. Tests can be taken anywhere, anytime, by anybody.

It uses a saliva (spit) sample as opposed to a nasal or throat swab, or blood.  This makes it easier and more comfortable to take the test.

We are developing the test in collaboration with the University of Waterloo (Canada) and its Institute of Nanotechnology.

Pre-Transfusion Blood Screening

A ground-breaking molecular paper-based rapid test.  A Lab-In-Hand device that screens for 6 transfusion-transmitted infections simultaneously. Accurate lab-like results in 20-minutes with no equipment or power supply are required.

Powerful Lab-In-Hand Features

Enabled through the convergence of the latest biosensing, nanotechnology, chemistry, biomaterials, and artificial intelligence technologies. 

Highly Accurate

Molecular lab-like accuracy (selectivity & sensitivity)

Extremely Low Cost To Produce

Low materials and manufacturing costs

No Technical Expertise Required

Tests can be taken by anyone, anywhere, anytime

Extreme Portability

Test anywhere, anytime, by anyone with no equipment, power supply, or technican required

Digitalized Results

Test results are shareable online via cell phone

Quick Results

Results are available in less than 20 minutes on the device, on the spot

Rapid, Low Cost, Low-Risk R&D to Commercialization

Identify & Acquire

– Paper-based microfluidic technologies and devices that solve a problem of an unmet need.

– Only those that possess robust testing data (preclinical or clinical).

Validate

– We have deep-domain experts from multiples disciplines (science, regulatory, manufacturing, and licensing).

– We optimize the devices into their final product, and take them through clinical trials, and onto commercialization.

– We obtain commercial validation from prospective commercial partners.

Changing Testing, Changing Lives.